Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Strategie cognitive per ottimizzare la salute del cervello e gestire i fattori di rischio vascolare transgenerazionale post-ictus (CHAMPS-TR)

16 novembre 2026 aggiornato da: University of New Mexico

Strategie cognitive per ottimizzare la salute del cervello e gestire i fattori di rischio vascolare transgenerazionale post-ictus (CHAMPS per il rischio transgenerazionale)

People living with the cognitive effects of stroke are at risk for recurrent stroke and further cognitive decline. Also problematic is that stroke risk clusters in families and biological family members of people who have ischemic stroke may also be at increased risk of stroke and/or cognitive decline. The primary goal of this study is to test the feasibility of a virtually delivered cognitive strategy training and health coaching program to reduce vascular risk and promote brain health in persons with stroke and their biological family members.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

CHAMPS for Transgenerational Risk (TR) (Cognitive strategies for optimizing brain Health And Managing transgenerational vascular risk factors Post-Stroke), a feasibility trial for preventing stroke and improving cognitive outcomes in persons with stroke and their families. Stroke is used as a vector to identify both persons with post-stroke cognitive impairment and dementia (PSCID)and a targeted family member who may be at risk and could benefit from vascular risk reduction intervention. The investigators integrate the concept of a "teachable moment" where health events can lead to behavior change by targeting family members who are stroke-free but may have vascular risk factors putting them at risk for stroke and vascular cognitive impairment (VCI) in the future. Recognizing that people with stroke frequently encounter barriers to community mobility, the proposed trial will be offered virtually to give even those with difficulty accessing the community an equitable opportunity to participate in clinical research.

In this feasibility trial, the investigators will pilot test the CHAMPS-TR intervention which includes vascular risk reduction coaching and a metacognitive problem-solving protocol which contains guided discovery, goal setting, and strategy training. Index persons with stroke and targeted family members (i.e., biological child, younger sibling) who may be at heightened risk for stroke and VCI will receive the CHAMPS intervention which will be delivered remotely. Participants will be split into two arms and either receive the virtual CHAMPS-TR intervention or CHAMPS-TR intervention plus remotely-supervised transcranial Direct Current Stimulation (RS-tDCS) based on eligibility and preference. tDCS is a minimally invasive brain stimulation technique that may augment the effects of cognitive interventions alone. It has strong evidence in stroke rehabilitation and RS-tDCS is a feasible approach in those with stroke and other clinical populations. The overarching goal of this project is to rigorously test the custom-tailored intervention for families impacted by ischemic stroke.

Tipo di studio

Interventistico

Iscrizione (Stimato)

40

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87131
        • University of New Mexico Health Sciences Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. primary diagnosis of acute ischemic stroke,
  2. impairment of cognitive function (score >1 on Quick Executive Interview - telephone screener),
  3. absence of severe aphasia (score of 0 or 1 on NIH Stroke Scale),
  4. absence of pre-stroke dementia (client report),
  5. absence of major anxiety and depressive disorder (PHQ-9, GAD-7),
  6. absence of drug and alcohol misuse within 3 months of study (AUDIT, DAST),
  7. greater than 40 years of age,
  8. having a potential family member who meets targeted family member criteria,
  9. eligible for MRI and Remote Supervised-transcranial direct current stimulation (RS-tDCS) if in CHAMPS-TR plus RS-tDCS (e.g., not pregnant; no intracranial metal implants; no skin lesions on target sites for stimulation; no severe cardiopulmonary, renal or hepatic diseases; no pacemakers; no underlying medical reason for not engaging in MRI or tDCS).

The targeted family member will be:

  1. a minimum of 18 years of age,
  2. biological kin of person with stroke,
  3. absence of dementia (client report),
  4. absence of major anxiety and depressive disorder (PHQ-9, GAD-7),
  5. absence of drug and alcohol misuse within 3 months of study (AUDIT, DAST),
  6. greater than 18 years of age, and
  7. having a sibling or parent who had an ischemic stroke

Exclusion Criteria:

For all participants:

  1. not English speaking, reading, and understanding, and
  2. no access to video-conference software on a computer or smart device

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: CHAMPS-TR

Persons with stroke and a targeted biological family member will receive the CHAMPS intervention including vascular risk reduction coaching and cognitive strategy training.

Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC).

Sperimentale: CHAMPS TR plus remotely supervised transcranial direct current stimulation (RS-tDCS)

Persons with stroke and a targeted biological family member will receive the CHAMPS intervention including vascular risk reduction coaching and cognitive strategy training. Persons with stroke will also receive RS-tDCS.

Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
American Heart Association Life's Essential 8 Metrics
Lasso di tempo: baseline, up to 7 weeks, and up to 24 weeks

metric scores for vascular risk; score is calculated on a 0-100 scale where 100 is ideal

baseline, up to 7 weeks, and up to 24 weeks
Cardiovascular risk factors, Aging, and Incidence of Dementia (CAIDE)
Lasso di tempo: baseline, up to 7 weeks, and up to 24 weeks

Risk profile score for cognitive decline; score is composed of weightings by reference to age, sex, education, systolic blood pressure, BMI, total cholesterol, and physical activity. Scores range from 0-15 with higher scores indicating greater risk.

baseline, up to 7 weeks, and up to 24 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Oral Trail Making Test Part B
Lasso di tempo: baseline and up to 24 weeks

Test of mental sequencing and switching; score with total number of seconds to complete up to 300, total number of errors, and total correct

baseline and up to 24 weeks
Number Span Test Forward and Backward
Lasso di tempo: baseline and up to 24 weeks

Test of working memory; scored with number of correct trials (0-14), and longest span forward (0, 3-9) and longest span backward (0, 2-8). Higher numbers are greater number of correct items.

baseline and up to 24 weeks
Multiple Errands Test Home Version
Lasso di tempo: baseline and up to 24 weeks

Test of executive function impact on everyday life; total score of 0-14 with higher levels indicating less impairment; additional sub-scores for errors made and strategies used using total scores.

baseline and up to 24 weeks
Mark VCID2 Clinical Cognitive Assessment Battery
Lasso di tempo: baseline and up to 24 weeks

Test of cognitive impairment and dementia; total scores on all sub-scores for each included measure.

baseline and up to 24 weeks
PROMIS Self-Efficacy for Managing Medications
Lasso di tempo: baseline, up to 7 weeks, and up to 24 weeks

Test of self efficacy for managing medications; scoring with item-level calibrations using HealthMeasures Scoring Service

baseline, up to 7 weeks, and up to 24 weeks
PROMIS Self-Efficacy for Managing Symptoms
Lasso di tempo: baseline, up to 7 weeks, and up to 24 weeks

Test of self efficacy for managing symptoms; scoring with item-level calibrations using HealthMeasures Scoring Service

baseline, up to 7 weeks, and up to 24 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

12 ottobre 2023

Completamento primario (Effettivo)

30 giugno 2026

Completamento dello studio (Stimato)

1 febbraio 2027

Date di iscrizione allo studio

Primo inviato

14 giugno 2024

Primo inviato che soddisfa i criteri di controllo qualità

26 giugno 2024

Primo Inserito (Effettivo)

28 giugno 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Data Sharing Plan

The investigators will share data collected in this project:

At National Scientific Meetings: The investigators expect to share results from the data at two conferences/scientific meetings a year such as the American Congress of Medical Rehabilitation Conference, the RESNA conference, the American Occupational Therapy Conference, and Aging Conferences.

Through Publication in Scientific Journals: the investigators expect to publish 1-2 journal articles a year where data from the proposed project will be shared with no subject identifiers.

Data to be shared includes de-identified: MRI data, feasibility data, self-efficacy scores, vascular risk factor scores, cognitive/executive function scores

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi